Bimagrumab and myostatin blockers: muscle, fat, and what the studies showed
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Bimagrumab and myostatin blockers: muscle, fat, and what the studies showed

Bimagrumab and myostatin blockers: how they change muscle and fat, what studies showed in obesity and sarcopenia, the approved apitegromab for SMA, and who should see a doctor first.

Bimagrumab and myostatin blockers: muscle, fat, and what the studies showed
Bimagrumab and myostatin blockers change body composition: muscle grows, fat goes down. What studies showed about strength and function, what is approved for SMA, and who should see a doctor first.

Key points

Myostatin blockers are antibodies and related proteins that release the "brake" on muscle growth. The best studied of them, bimagrumab, does change body composition in studies: muscle is gained, fat goes. In the BELIEVE study (507 people with obesity, 1 study, 48 weeks) weight fell by 9.3 kg on bimagrumab 30 mg/kg, by 14.2 kg on semaglutide 2.4 mg and by 17.8 kg on the combination of these doses versus 3.3 kg on placebo (56–57 people per group), and lean mass rose by 1.0–1.1 % on bimagrumab but fell by 4.7–6.9 % on semaglutide. Strength and function behaved differently from mass: in the largest sarcopenia study (180 people) lean mass rose by 7 % versus 1 %, while the result of physical tests (+1.34 versus +1.03 points, P = 0.13) did not differ significantly from placebo. Of the whole class, the US regulator (FDA) has approved one drug, apitegromab, and only for spinal muscular atrophy. Bimagrumab is not registered, and the other uses remain in research. Related topics: GLP-1 agonists and weight loss, strength training twice a week and the peptide MOTS-c and the muscle response to exercise.

Substance and formWhat it doesWhat studies showedWho it is discussed for
Bimagrumab, intravenous, obesityblocks type II activin receptors507 people, 1 study, 48 weeks: weight −9.3 kg versus −3.3 kg on placebo; lean mass +1.0…+1.1 %adults with obesity, in a study
Bimagrumab, intravenous, sarcopeniathe same180 people, 1 study: lean mass +7 % versus +1 %, physical tests no different from placeboolder people, in a study
Landogrozumab and domagrozumabbind mature myostatin201 people, 1 study: appendicular lean mass +0.43 kg versus placebo; 120 boys with Duchenne muscular dystrophy, 1 study: the time to climb four steps did not differ significantly (p = 0.94)older people and children with muscular dystrophy, programs closed
Apitegromab (Isembyld), intravenousblocks the activation of myostatin156 children aged 2–12 of 188, 1 study: +1.8 points on the motor function scale versus placebo (two doses together)spinal muscular atrophy from age 2 together with background therapy (FDA indication)

How it works

Myostatin is a protein that normally limits the growth of muscle tissue. Drugs of the class interfere with this signal in three ways. Bimagrumab occupies the type II activin receptors themselves, so it switches off myostatin, activins and the related protein GDF-11 at once: hence the effect on both muscle and fat, and the side effects outside muscle. Landogrozumab, domagrozumab, stamulumab and taldefgrobep bind ready-made myostatin, and their results on muscle mass are more modest. Apitegromab binds the myostatin precursors and does not touch the mature protein. One caveat from the diabetes study itself: the authors did not measure total body water, so part of the gain in "lean mass" may be water.

Obesity: fat goes, muscle stays

The strongest picture comes from people with obesity. BELIEVE enrolled 507 people (56–57 per group); diabetes was excluded, and everyone received a diet with a 500 kcal deficit, at least 1.2 g/kg of protein per day and 150 minutes of activity per week. Bimagrumab was given intravenously: two loading doses, then every 12 weeks; semaglutide 2.4 mg was given subcutaneously once a week. Over 48 weeks fat mass fell by 13.0–18.9 % on bimagrumab, by 16.0–21.1 % on semaglutide and by 24.7–33.7 % on the combination versus 5.6 % on placebo. The share of weight loss that came from fat was 100 % on bimagrumab 30 mg/kg and 71.1 % on semaglutide. In the open-label extension to week 72 (post hoc analysis) the combination gave −24.2 kg (−22.1 %), while lean mass changed by −2.9 % versus −7.4 % on semaglutide and +2.5 % on bimagrumab.

Blood sugar responded less: by week 72 HbA1c (glycated hemoglobin) fell by 0.23 % (≈ −2.5 mmol/mol) on bimagrumab versus 0.40 % (≈ −4.4 mmol/mol) on semaglutide. Well-being and function stayed at the placebo level: the SF-36 physical functioning score did not differ significantly from placebo, and hand grip strength rose significantly in only one group of nine. The authors stress that no adjustment for multiple comparisons was made and the results should not be considered final; the study was carried out on commission from Eli Lilly.

An earlier study in people with type 2 diabetes and obesity (75 randomized, analysis on 26 versus 29 people, 48 weeks) showed the same pattern: fat mass −7.49 kg versus −0.18 kg, lean mass +1.70 kg versus −0.44 kg, HbA1c −0.76 % (≈ −8 mmol/mol) versus almost unchanged on placebo (0.04 %, ≈ 0.4 mmol/mol). The significance thresholds there are one-sided, 10 %, and the intervals are 80 %, as the paper states directly, and hand grip strength did not change. A meta-analysis of four studies (268 people) gives modest averaged figures: weight −4.85 kg (95 % CI −6.82…−2.88), lean mass +1.66 kg. The earliest observation of the same pattern is a pilot in 16 people with insulin resistance: after a single dose lean mass rose by 2.7 % and fat mass fell by 7.9 % (P = 0.011), while weight stayed the same, because there was no diet or exercise in that study.

Sarcopenia and age: mass grows, tests stay the same

Sarcopenia is the age-related loss of muscle mass and strength. In the largest study (180 people aged 70 and older, 38 centers in 13 countries, 1 study, bimagrumab 700 mg monthly for 6 months) everyone received adequate nutrition and home exercise. Lean mass rose by 7 % (95 % confidence interval, below CI, 6–8) versus 1 % on placebo, a difference of 6 % (4–7), P < 0.001. The main measure, the Short Physical Performance Battery (SPPB), rose by 1.34 versus 1.03 points (P = 0.13), the six-minute walk distance by 24.6 versus 14.3 m (P = 0.16), and walking speed by 0.14 versus 0.11 m/s (P = 0.16). Physical function improved in both groups, and the authors link this to nutrition and exercise. In an earlier pilot of 40 people, walking speed and distance rose only in the subgroup with initially slow walking; in the large study there was no difference from placebo in function.

The same pattern repeated in other situations. After surgery for hip fracture (250 people, 1 study, 24 weeks) lean mass rose by 2.8 kg on the 700 mg dose versus 0.2 kg on placebo, while walking speed and the SPPB result did not differ between groups; the number of falls was the same: 17–19 % versus 18 %. In chronic obstructive pulmonary disease (COPD) with low muscle mass (67 people, 1 study) thigh muscle volume rose by 5.0 % versus −1.3 %, and the six-minute walk distance did not increase significantly in either group. After two weeks in a cast in 24 healthy men (15 received the drug, 9 placebo) thigh muscle volume recovered faster (+5.1 % versus −0.1 % from baseline), and knee extension strength returned to baseline within 6 weeks in both groups. A meta-analysis of seven studies summarized it this way: thigh muscle volume +5.29 % (95 % CI 4.08–6.50), fat-free mass +1.90 kg, and no significant improvement in strength and walking speed.

Antibodies to myostatin itself produced a smaller shift. Landogrozumab in 201 older people with falls (1 study, 24 weeks) increased appendicular lean mass by 0.43 kg (95 % CI 0.192–0.660); some of the functional tests reached significance only at a threshold relaxed in advance to 0.1. In 400 people after hip replacement the prespecified threshold for muscle mass was not met.

Muscle diseases: Duchenne and inclusion body myositis

In Duchenne muscular dystrophy domagrozumab was given to 80 boys aged 6–16 versus 40 on placebo: the time to climb four steps changed by +0.27 s (95 % CI −7.4…7.9), p = 0.94. Taldefgrobep in Duchenne did not reach the threshold of the prespecified analysis (at least +1.5 points on the North Star scale), and the program was closed in 2019. In inclusion body myositis (251 people, 1 study, 52 weeks) the difference in walking from placebo was +17.6 m at 10 mg/kg (99 % CI −19.6…54.8, p = 0.22); in the extension of 211 people the distance declined in all groups. Falls were the most frequent event in all groups of this study: 76–87 % versus 84 % on placebo. Earlier still, stamulumab was given to 116 adults with Becker, facioscapulohumeral and limb-girdle dystrophy: there were no improvements in strength and function in the exploratory measures, and skin hypersensitivity was noted at high doses. A systematic review of 14 studies in inclusion body myositis found no drug with an effect on the course of the disease.

Spinal muscular atrophy: the approved indication

Apitegromab (Isembyld) was approved by the FDA on September 11, 2026 for the treatment of spinal muscular atrophy (SMA) in adults and children from age 2 who already receive a drug aimed at the SMN2 gene. It is an add-on to background therapy, not a replacement. The approval rests on the SAPPHIRE study: 188 people aged 2–21, all already receiving nusinersen or risdiplam; 128 received apitegromab and 60 placebo. The main result was calculated in 156 children aged 2–12: over a year motor function on the Hammersmith Functional Motor Scale Expanded (HFMSE, maximum 66 points) rose by 1.8 points (95 % CI 0.30–3.32; p = 0.019) relative to placebo with the doses pooled. For the 10 mg/kg dose, separately, the FDA label gives +2.2 points (95 % CI 0.49–3.95; 53 versus 50 people), and improvement of at least 3 points in 34.2 % versus 13.5 %. For 20 mg/kg the difference of +1.4 points (−0.34…3.13; p = 0.11) was not significant, and this dose is not recommended in the label. These are different calculations of one study and should not be mixed. An earlier study (TOPAZ, 58 people, no placebo) gave a change from baseline of −0.3 points (23 people), +0.6 (15) and +7.1 (9 children on 20 mg/kg in the third group).

Safety

The most frequent events with bimagrumab are muscle spasms and diarrhea. In the diabetes study (37 versus 38 people) spasms occurred in 41 % versus 3 %, diarrhea in 41 % versus 11 %, and treatment was stopped because of adverse events in 5 people (14 %) versus 0. In BELIEVE, treatment was stopped because of adverse events by 14.0–21.4 % on bimagrumab alone versus 3.6 % on placebo; acne was common. In the meta-analysis the relative risk was 10.44 for spasms (95 % CI 4.23–25.75) and 4.91 for diarrhea (2.38–10.11), and low-density lipoprotein (LDL) rose by 0.47 mmol/L (≈ 18 mg/dL); in BELIEVE, on bimagrumab alone LDL rose by 17.6 % by week 72. Hip bone density fell by 2.1 % on semaglutide 2.4 mg and by 2.0–2.3 % on the three combinations versus 0.8 % on placebo. In women aged 55–75, by week 8 bimagrumab lowered follicle-stimulating hormone by 42.16 IU/L relative to placebo (the same units in the US system), and in men there was no such shift; the effect is reversible. The telangiectasias and blood abnormalities that stopped the trial of the ACE-031 receptor trap were not seen in BELIEVE. Serious adverse events in BELIEVE were noted in 8.8–12.5 % in the bimagrumab groups versus 3.6 % on placebo, and there were no deaths. The heart was assessed in 68 healthy people aged 60–86 over 6 months: left ventricular mass index +1.6 g/m² (90 % CI −0.2…3.4, P = 0.148), with no clinically significant change.

With landogrozumab in pancreatic cancer (125 people, chemotherapy plus the drug) overall survival turned out worse: hazard ratio (HR) 1.70 (90 % CI 1.1–2.7) for 300 mg; this group was closed in August 2014 because of an excess of deaths. In the apitegromab label the only warning is fractures, including serious ones: in 5 of 53 people (9 %) on 10 mg/kg and in 3 of 53 (6 %) on 20 mg/kg versus 1 of 53 (2 %) on placebo, and three treated people had a femur fracture. In the extension on 20 mg/kg fractures were noted in 22 people (9 %), five of them serious hip fractures.

How it is used

Only apitegromab has a registered regimen: 10 mg/kg intravenously once every 4 weeks, an infusion of 60–120 minutes at a rate of no more than 150 mL/h, diluted in 0.9 % sodium chloride solution; the indication is SMA from age 2 together with background therapy. The 20 mg/kg dose is not directly recommended in the label. In studies bimagrumab was given intravenously: in obesity 10 or 30 mg/kg (two loading doses, then every 12 weeks), in sarcopenia 700 mg monthly for 6 months, after hip fracture surgery 70, 210 or 700 mg every 4 weeks, in inclusion body myositis 1, 3 or 10 mg/kg every 4 weeks for at least 48 weeks. Subcutaneous administration of bimagrumab appears only in a phase 1 pharmacokinetic study: 91 people aged 70 and older were assigned to seven groups, and some of them received the drug subcutaneously, as an infusion of 1500 or 525 mg every 4 weeks or weekly 300, 150 or 52.5 mg; the 52.5 mg subcutaneous dose did not differ from placebo, and bioavailability with subcutaneous administration was about 40 %. No drug of the class is registered for gaining muscle, for aging or for athletes.

Who should see a doctor first

The only regulator label in this class is that of apitegromab, and treatment should be discussed with a doctor before starting in the cases the document itself names. Fractures, including serious ones, are placed in it as a warning: some fractures occurred without an obvious cause such as a fall, so past fractures and the condition of the bones are reviewed in advance. Hypersensitivity is on the list of the most common reactions, which occurred in at least one in five. Pregnancy: the label warns of possible harm to the fetus. In children under 2 years safety and efficacy are not established in the label; the indication starts at age 2 and only together with therapy aimed at the SMN2 gene. The 20 mg/kg dose is not recommended in the label. The drug is given intravenously in a clinic under supervision, and is not taken on one's own.

What the studies showed

What was studiedWho and how manyResultSource
Obesity, bimagrumab with semaglutide507 people, 56–57 per group, 1 study, 48 weeksweight −9.3 kg (bimagrumab 30 mg/kg), −14.2 kg (semaglutide 2.4 mg), −17.8 kg (combination of these doses) versus −3.3 kg; lean mass +1.0…+1.1 % versus −4.7…−6.9 % on semaglutideHeymsfield Nat Med 2026. PMID 41772149
Type 2 diabetes and obesityanalysis on 26 versus 29 people of 75, 1 study, 48 weeksfat −7.49 kg versus −0.18 kg; lean mass +1.70 kg versus −0.44 kg; HbA1c −0.76 % (≈ −8 mmol/mol) versus 0.04 % (≈ 0.4 mmol/mol); hand grip strength no differentHeymsfield JAMA Netw Open 2021. PMID 33439265
Obesity and metabolism, meta-analysis268 people, 4 studiesweight −4.85 kg; lean mass +1.66 kg; LDL +0.47 mmol/L (≈ 18 mg/dL)Shao Diabetes Obes Metab 2026. PMID 42530342
Insulin resistance, single dose16 people, 1 studylean mass +2.7 %, fat −7.9 %, weight unchangedGarito Diabetes Obes Metab 2018. PMID 28643356
Sarcopenia, 24 weeks180 people, 1 studylean mass +7 % versus +1 %; SPPB +1.34 versus +1.03 (P = 0.13), no significant differenceRooks JAMA Netw Open 2020. PMID 33074327
Sarcopenia, meta-analysis7 studiesthigh muscle volume +5.29 %; no improvement in strength and walking speedKanbay Aging Clin Exp Res 2024. PMID 39251484
After hip fracture250 people, 1 study, 24 weekslean mass +2.8 kg versus +0.2 kg (700 mg); walking speed and SPPB no differentHofbauer Lancet Healthy Longev 2021. PMID 36098133
COPD with low muscle mass67 people, 1 study, 24 weeksthigh muscle volume +5.0 % versus −1.3 %; six-minute walk distance did not increase significantly in either groupPolkey Am J Respir Crit Care Med 2019. PMID 30095981
Older people with falls, landogrozumab201 people, 1 study, 24 weeksappendicular lean mass +0.43 kg (95 % CI 0.192–0.660)Becker Lancet Diabetes Endocrinol 2015. PMID 26516121
Pancreatic cancer, landogrozumab125 people, 1 studyoverall survival worse: HR 1.70 (90 % CI 1.1–2.7) for 300 mgGolan J Cachexia Sarcopenia Muscle 2018. PMID 30051975
Duchenne muscular dystrophy, domagrozumab120 boys, 1 studytime to climb four steps +0.27 s versus placebo, p = 0.94Wagner Neuromuscul Disord 2020. PMID 32522498
Inclusion body myositis251 people, 1 study, 52 weekswalking +17.6 m (99 % CI −19.6…54.8), p = 0.22Hanna Lancet Neurol 2019. PMID 31397289
Spinal muscular atrophy, phase 3156 children aged 2–12 of 188, 1 study+1.8 points versus placebo (two doses together; 95 % CI 0.30–3.32), p = 0.019; 20 mg/kg alone p = 0.11Crawford Lancet Neurol 2025. PMID 40818473
Spinal muscular atrophy, phase 258 people, 3 groups, 1 studychange from baseline without placebo: −0.3 points (23 people), +0.6 (15), +7.1 (9)Crawford Neurology 2024. PMID 38330285
Heart over 6 months of blockade68 healthy people aged 60–86, 1 studyleft ventricular mass index +1.6 g/m² (90 % CI −0.2…3.4), P = 0.148, no clinically significant changeRooks J Clin Endocrinol Metab 2026. PMID 41873146

Summary

Myostatin blockers change body composition: for bimagrumab the result on fat is comparable to semaglutide (this comparison refers to week 72 of one phase 2 study in 507 people, that is, to the open-label period and a post hoc analysis), and muscle does not leave together with the weight. At the same time, strength and physical function in the studies went separately from mass: mass grew, while the test result did not differ significantly from placebo. One indication is approved, SMA with background therapy; the other uses remain in research. If you are interested in muscle mass during weight loss or after 60, you can discuss nutrition, strength training and indications at a consultation.

Source: Bimagrumab and myostatin blockers: muscle, fat, and what the studies showed — universum.earth. Dr. Pereligyn.

Come back
Request a call back